PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Texas Children\'s Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine , Houston, TX, USA.\', \'National School of Tropical Medicine, Baylor College of Medicine , Houston, TX, USA.\', \'Molecular Virology & Microbiology, Baylor College of Medicine , Houston, TX, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/21645515.2020.1740560
?:hasPublicationType
?:journal
  • Human vaccines & immunotherapeutics
is ?:pmid of
?:pmid
?:pmid
  • 32298218
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all